Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 799 across all filing types
Latest filing 2022-08-01 Regulatory Filings
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS
Regulatory Filings Classification · 100% confidence The document is a press release dated August 1, 2022, announcing that the European Medicines Agency (EMA) granted accelerated assessment for the Marketing Authorisation Application (MAA) for the drug leniolisib for APDS. It details the implications of this assessment (shorter review time) and confirms the company is on track to submit the MAA in H2 2022 (specifically October 2022). It also includes clinical data summaries, management commentary, and background information on the disease and the drug. This type of announcement, focusing on regulatory milestones and clinical progress leading up to a major filing, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is a formal announcement of key operational/regulatory news rather than a full financial report (10-K, IR) or a transcript (CT), and it is not specifically about management changes (MANG), director dealings (DIRS), or dividends (DIV), the most fitting category is Earnings Release (ER), as these press releases often accompany or precede quarterly financial reporting periods, even if the primary focus here is regulatory news. Given the context of a major regulatory update, it is a high-impact corporate announcement.
2022-08-01 English
Pharming Group presenteert tijdens de Jefferies Healthcare Conference
Regulatory Filings Classification · 100% confidence The document is a short press release dated June 2, 2022, announcing that the CEO of Pharming Group N.V. will present at the Jefferies Healthcare Conference 2022 on June 9, 2022. It provides details about the conference, company background, and includes standard forward-looking statements and contact information. This type of announcement, which informs the market about an upcoming corporate event (like a conference presentation) without being a full financial report, management change, or dividend notice, typically falls under general regulatory announcements or investor relations updates. Since there is no specific category for 'Conference Presentation Announcement,' and it is a formal communication to the market, it best fits the 'Regulatory Filings' (RNS) category as a general regulatory disclosure, or potentially 'Investor Presentation' (IP) if the presentation material itself was attached, but here it is only an announcement *about* the presentation. Given the nature of the announcement (a brief update on corporate activity), RNS is the most appropriate general disclosure category.
2022-06-02 English
Pharming Group presenteert tijdens de Jefferies Healthcare Conference
Investor Presentation Classification · 95% confidence The document is a press release dated June 2, 2022, announcing that the CEO of Pharming Group N.V. will be presenting at the Jefferies Healthcare Conference on June 9. This is an announcement about the company's participation in an external industry event, which is typically classified as investor relations communication. Since the document is a short press release announcing an upcoming presentation at a conference focused on investment opportunities, it aligns best with the Investor Presentation (IP) category if it were the presentation itself, or more generally, a communication aimed at investors regarding corporate activities. However, none of the categories perfectly fit an announcement of a presentation at a third-party conference. Given the options, this is a general corporate update aimed at investors about an upcoming event where company information will be shared. It is not a formal regulatory filing (10-K, IR, ER, MRQ), nor is it a management change (MANG) or dividend notice (DIV). It is an announcement of an event where an investor presentation might occur. In the context of financial filings, announcements about executive participation in major industry conferences are often grouped with Investor Presentations (IP) or general Regulatory Filings (RNS). Since the content is an announcement about an upcoming presentation, and not the presentation itself, and it doesn't fit other specific categories, RNS (Regulatory Filings - fallback) is a possibility, but IP (Investor Presentation) often covers materials related to investor outreach events. Given the nature of the event (Healthcare Conference with investors), classifying it as an Investor Presentation (IP) related announcement is the most contextually relevant choice, even though it's just the announcement of the presentation, as it signals forthcoming investor engagement.
2022-06-02 Dutch
6-K
Regulatory Filings
2022-06-02 English
Pharming Press release AGM 2022
AGM Information Classification · 98% confidence The document is a press release dated May 18, 2022, announcing that all proposals were approved during the 'Algemene Vergadering van Aandeelhouders' (Annual General Meeting of Shareholders - AVA). It specifically mentions the approval of the 2021 annual accounts, discharge of the Board of Directors, and voting on remuneration reports and authorizations for share issuance/buybacks. This content directly relates to the proceedings and outcomes of the AGM. Therefore, the most appropriate classification is AGM Information (AGM-R). Although it is a press release, its primary function here is to report the results of the AGM, making AGM-R more specific than RPA or RNS.
2022-05-19 Dutch
Pharming Press release AGM 2022
AGM Information Classification · 99% confidence The document explicitly states it is announcing that 'all proposals [were] approved' at the 'Annual General Meeting of shareholders (AGM)'. It details the approval of financial statements, discharge to the Board, and authorization for share issuance/repurchase, which are typical agenda items for an AGM. This content directly relates to the proceedings and outcomes of the Annual General Meeting. Therefore, the most appropriate classification is AGM Information (AGM-R). The document is a summary announcement of the results, not the full presentation slides or the voting results declaration itself.
2022-05-19 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.